Strategies for first line HIV therapy

May 2008     View PDF

Entry and integrase inhibitors

The other two classes of HIV drugs are not recommended for first line use. The fusion inhibitor Fuzeon (enfuvirtide/T20) hasn’t been studied in this way, and it’s given as a shot twice a day. The CCR5 drug Selzentry (maraviroc) has been studied as part of first line therapy, but it failed to match up to Sustiva’s potency. The integrase inhibitor Isentress (raltegravir) is now being studied, but very little data have been seen from it.